nivolumab,polatuzumab vedotin,ipilimumab
roche,bms
['pola', 'cm914']
intriguing data from cm914 .does the pdl1+ population appear to derive benefit? hard to extrapolate from subgroup analysis. #asco2023 
GU medical oncologist @UCSanDiego, mom, wife, avid runner. Kidney and prostate cancer research. Tweets are my own and not medical advice.